Latest Us Market News

Nova Minerals' US holding company shares and warrants are slated to begin trading on NYSE American on 17 June 2026, with ASX trading of CHESS Depositary Interests following on 18 June, marking a key step in the company’s US redomiciliation.

Vitrafy Life Sciences has secured A$30 million through an institutional placement to ramp up manufacturing of its Guardion cryopreservation devices and expand US sales operations, with an additional A$2 million sought via a shareholder plan.

Imricor Medical Systems has submitted the third of four Premarket Approval modules to the FDA, marking a key step towards US approval of its MR-guided cardiac ablation devices.

LTR Pharma has locked in Strive Specialties as its exclusive US pharmacy fulfilment partner for ROXUS, marking a critical step towards commercial launch in the US erectile dysfunction market.

Eden Innovations has wrapped up the second tranche of its $4 million institutional placement, issuing over 14 million shares at 18 cents each. The capital injection finalises the raise announced in April, with shares issued under ASX rules and ranking equally with existing stock.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

LTR Pharma has secured a binding US telehealth commercialisation framework for its intranasal erectile dysfunction treatment ROXUS, committing to at least 150,000 prescriptions in the first year and granting exclusivity to Shed Holdings' platform.

ArborGen Holdings announces CEO Justin Birch's resignation after three years, appointing Patrick Cumbie as interim CEO while searching for a permanent replacement.

GCM Corporation is seeking shareholder approval for a 15-to-1 share consolidation as a strategic step towards a potential listing on a US national stock exchange, aiming to boost international capital access and market visibility.

First Graphene accelerates its US expansion by acquiring MITO Material Solutions, gaining functionalised graphene technologies and a direct commercial foothold in the world’s largest defence and aerospace market.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.

Pacific Edge has secured NZ$36.1 million through a combination of a NZ$25.4 million placement and a significantly oversubscribed retail offer, reinforcing its strategic position to expand the Cxbladder cancer diagnostic platform.